Enzalutamide

XTANDI ® is indicated for the treatment of patients with: castration-resistant prostate cancer (CRPC) metastatic castration-sensitive prostate cancer (mCSPC) non‑metastatic castration‑sensitive prostate cancer (nmCSPC) with biochemical…

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: castration-resistant prostate cancer (CRPC)
metastatic castration-sensitive prostate cancer (mCSPC)
non‑metastatic castration‑sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR)

What it is used for

XTANDI ® is indicated for the treatment of patients with:

castration-resistant prostate cancer (CRPC)
metastatic castration-sensitive prostate cancer (mCSPC)
non‑metastatic castration‑sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR)

Side effects, and when to stop

The following adverse reactions are discussed in more detail in other sections of the labeling:

Seizure
Posterior Reversible Encephalopathy Syndrome (PRES)
Hypersensitivity
Ischemic Heart Disease
Falls and Fractures
Dysphagia or Choking

Who should not take it

None.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Enzalutamide; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/enzalutamide
APA 7th: sofidex. (2026, August 2). Enzalutamide. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/enzalutamide
AMA 11th: Enzalutamide. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/enzalutamide

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.